查詢結果分析
相關文獻
- 慢性B型肝炎治療現況
- B型肝炎的醫學大躍進--將分子生物學方法應用於臨床診斷
- Tenofovir慢性B型肝炎治療新藥
- 大溪地等鞭金藻抗B型肝炎病毒野生型及Lamivudine抗藥性突變株作用之探討
- Drug Resistance Patterns of Tuberculosis in Taiwan
- 臺灣東北部地區出現的Vancomycin 抗藥性腸球菌
- 醫療尖銳物品扎傷追蹤調查
- Heterogeneity of Resistance Elements in Clinical Isolates of Enterococci with High-Level Gentamicin Resistance
- 偵測多種抗藥性結核桿菌的最新發展
- Control of Hepatitis B Virus Infection by Vaccination: The Taiwan Experience
頁籤選單縮合
題 名 | 慢性B型肝炎治療現況=Treatment of Chronic Hepatitis B |
---|---|
作 者 | 張芳瑀; 顧曉耘; | 書刊名 | 藥學雜誌 |
卷 期 | 29:3=116 2013.09[民102.09] |
頁 次 | 頁62-67 |
分類號 | 418.285 |
關鍵詞 | B型肝炎病毒; 核苷/核苷酸; 抗藥性; Hepatitis B virus; Resistance; |
語 文 | 中文(Chinese) |
中文摘要 | 慢性B型肝炎 (chronic hepatitis B, CHB) 是一個全球性的健康議題,主要由B型肝炎病毒 (hepatitis B virus, HBV) 所引起,估計全世界患病人數約有3.5-4億人,HBV 感染更是導致肝失償、肝硬化及肝細胞癌的主要原因1。目前慢性B型肝炎的治療藥物可分成干擾素和口服抗病毒藥品兩大類,口服抗病毒藥品包括核苷/核苷酸類似物 (nucleoside/nucleotide analogues, NAs) 如 lamivudine、adefovir、entecavir、telbivudine 及 tenofovir 等。此類藥品主要藉由阻斷 HBV 聚合酶的活性來抑制 HBV 的複製。其優點在於抑制病毒效果強、經口服給藥且耐受性佳,另外可以降低肝硬化及肝細胞癌的發生。但長期給藥容易產生抗藥性,因此在臨床上為了預防多重抗藥性突變株的出現,聯合治療將是未來治療 CHB 的重要趨勢。 |
英文摘要 | Hepatitis B virus (HBV) is one of the most serious and prevalent health problem, affecting more than 4 billion people worldwide and at risk of hepatic decompensation, cirrhosis, and hepatocellular carcinoma. The current available agents for the treatment of chronic hepatitis B (CHB) include immunomodulatory agents, such as conventional interferon-α, pegylated interferon-α, and oral nucleoside/nucleotide analogues (NAs), including lamivudine, adefovir, telbivudine, entecavir and tenofovir. The NAs work mainly by inhibiting hepatitis B virus DNA polymerase activity and thus suppress HBV replication. Oral NAs have become the mainstay of CHB treatment, mainly due to their profound viral suppressive effects and also due in part to the ease of single daily dosing and lack of significant side effects. In addition, long-term treatment with these antiviral agents is associated with a reduced risk of development of hepatocellular carcinoma. However, antiviral drug resistance is a major barrier to the success of long term treatment with NAs. In the future, combination therapy may prevent the emergence of multi-drug resistant mutants. |
本系統中英文摘要資訊取自各篇刊載內容。